3524-87-6

Basic information

• Product Name: 4-Hydroxy-6-methylpyrimidine
• Synonyms: 6-METHYL-PYRIMIDIN-4-OL;6-METHYL-4-PYRIMIDINOL;6-METHYL-4(3H)-PYRIMIDINONE;AKOS BC-0740;4-HYDROXY-6-METHYLPYRIMIDINE;4(1H)-Pyrimidinone, 6-methyl-;4-Pyrimidinol, 6-methyl-;6-methyl-4(1h)-pyrimidinon
• CAS NO: 3524-87-6
• Molecular Formula: C₅H₆N₂O
• Molecular Weight: 110.11
• EINECS: 222-543-4
• Product Categories: PYRIMIDINE;Pyridines, Pyrimidines, Purines and Pteredines;Pyrimidine series;Heterocycle-Pyrimidine series
• Mol File: 3524-87-6.mol
• Article Data: 24

Chemical Properties

• Melting Point: 145-150℃
• Boiling Point: 242.1±20.0 °C at 760 mmHg
• Flash Point: 100.2±21.8 °C
• Appearance: White to brown/Solid
• Density: 1.2±0.1 g/cm³
• Vapor Pressure: 0.496mmHg at 25°C
• Refractive Index: 1.576
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 9.46±0.40(Predicted)
• CAS DataBase Reference: 4-Hydroxy-6-methylpyrimidine(CAS DataBase Reference)
• NIST Chemistry Reference: 4-Hydroxy-6-methylpyrimidine(3524-87-6)
• EPA Substance Registry System: 4-Hydroxy-6-methylpyrimidine(3524-87-6)

Safety Data

• Hazard Codes: Xn
• Statements: 22-41
• Safety Statements: 26-39
• WGK Germany: 3
• RTECS: UW7528000
• TSCA: Yes
• HazardClass: IRRITANT
• Hazardous Substances Data: 3524-87-6(Hazardous Substances Data)

Usage

Uses

6-Methyl-4-hydroxypyrimidine is used in the preparation of antitumor compounds based upon adenine. Also used in the synthesis of novel purimidine, 3-cyanopyridine and m-amino-N-phenylbenzamide derrivatives as tyrosine kinase inhibitors.

InChI:InChI=1/C5H6N2O/c1-4-2-5(8)7-3-6-4/h2-3H,1H3,(H,6,7,8)

Upstream product

• 5424-21-5 2,4-dichloro-6-methylpyrimidine 
• 6328-58-1 6-methyl-2-methylsulfanyl-3H-pyrimidin-4-one 
• 109113-86-2 3-Formylamino-3-methyl-N-acetylacrylamide 
• 89991-24-2 2-(6-Methyl-pyrimidin-4-ylsulfanyl)-1-p-tolyl-ethanone 
• 3524-87-6 6-methyl-3H-pyrimidin-4-one 
• 56-04-2 6-methyl-2-thiouracil 
• 21731-17-9 methyl 3-aminocrotonate 
• 71-36-3 butan-1-ol 
• 17759-11-4 4-benzyloxy-6-methylpyrimidine 1-oxide 
• 37893-08-6 2-hydrazino-6-methylpyrimidin-4(3H)-one 
• 53907-67-8 N-(3-methyl-isoxazol-5-yl)-formamide 
• 56-04-2 6-methyl-2-thiouracil 
• 6328-58-1 4-Hydroxy-6-methyl-2-methylthiopyrimidine 
• 3473-63-0 formamidine acetic acid 

Downstream Products

• 51793-97-6 6-methylpyrimidine-4(3H)-thione 
• 7752-74-1 5-iodo-6-methyl-3H-pyrimidin-4-one 
• 83942-10-3 4,5-dichloro-6-methyl-pyrimidine 
• 3524-87-6 4-hydroxy-6-methylpyrimidine 
• 3524-87-6 6-methyl-3H-pyrimidin-4-one 
• 89991-27-5 2-(6-methyl-4-pyrimidinylthio)-cyclohexanone 
• 89991-26-4 ω-(6-methyl-4-pyrimidinylthio)-acetophenone 
• 89991-24-2 2-(6-Methyl-pyrimidin-4-ylsulfanyl)-1-p-tolyl-ethanone 
• 89991-22-0 1-(4-Chloro-phenyl)-2-(6-methyl-pyrimidin-4-ylsulfanyl)-ethanone 
• 89991-23-1 1-(4-Bromo-phenyl)-2-(6-methyl-pyrimidin-4-ylsulfanyl)-ethanone 
• 89991-25-3 1-(4-Methoxy-phenyl)-2-(6-methyl-pyrimidin-4-ylsulfanyl)-ethanone 
• 14027-64-6 1.3.6-Trimethyl-4-oxo-1H.4H-pyrimidinium-iodid 
• 7752-72-9 5-chloro-6-methyl-3H-pyrimidin-4-one 
• 912353-72-1 C₂₇H₂₈ClFN₄O₂ 

Relevant articles and documents

Visible-Light-Induced Radical Difluoromethylation/Cyclization of Unactivated Alkenes: Access to CF2H-Substituted Quinazolinones

A mild and efficient visible-light-induced radical difluoromethylation/cyclization of unactivated alkenes toward the synthesis of substituted quinazolinones with easily accessible difluoromethyltriphenylphosphonium bromide has been developed. The transformation has the advantages of wide functional group compatibility, a broad substrate scope, and operational simplicity. The benign protocol offers a facile access to pharmaceutically valuable difluoromethylated polycyclic quinazolinones.

5-Alkynyl-pyridines

This invention relates to 5-alkynyl-pyridine of general formula (I) their use as inhibitors of the activity of PI3Kalpha, pharmaceutical compositions containing them, and their use as a medicaments for the treatment and/or prevention of diseases characterized by excessive or abnormal cell proliferation and associated conditions such as cancer. The groups R1 to R6 and n have the meanings given in the claims and in the specification

5-ALKYNYL-PYRIMIDINES

The present invention encompasses compounds of general formula (1) wherein R1 to R4 R3 are defined as in claim 1, which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, and the use thereof for preparing a medicament having the above-mentioned properties.